Heron Therapeutics, Inc. (NASDAQ:HRTX) Position Increased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 0.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,105,803 shares of the biotechnology company’s stock after buying an additional 9,418 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.73% of Heron Therapeutics worth $1,692,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in HRTX. Y Intercept Hong Kong Ltd bought a new position in Heron Therapeutics in the 3rd quarter worth approximately $39,000. Capstone Investment Advisors LLC bought a new stake in shares of Heron Therapeutics during the third quarter valued at about $45,000. Glenmede Trust Co. NA lifted its holdings in Heron Therapeutics by 49.6% in the third quarter. Glenmede Trust Co. NA now owns 31,903 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 10,578 shares during the period. Cutter & CO Brokerage Inc. lifted its holdings in Heron Therapeutics by 69.6% in the fourth quarter. Cutter & CO Brokerage Inc. now owns 33,135 shares of the biotechnology company’s stock worth $51,000 after purchasing an additional 13,600 shares during the period. Finally, Intech Investment Management LLC bought a new position in Heron Therapeutics in the 3rd quarter valued at about $72,000. 80.01% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on HRTX shares. StockNews.com lowered shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, March 8th. Needham & Company LLC restated a “buy” rating and issued a $4.00 target price on shares of Heron Therapeutics in a research report on Friday, February 28th.

Heron Therapeutics Price Performance

Shares of HRTX opened at $2.26 on Friday. The firm’s 50 day moving average is $2.00 and its 200-day moving average is $1.78. Heron Therapeutics, Inc. has a 12-month low of $1.04 and a 12-month high of $3.93. The stock has a market capitalization of $344.27 million, a P/E ratio of -12.55 and a beta of 1.55.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.05. The company had revenue of $40.78 million during the quarter, compared to the consensus estimate of $37.37 million. As a group, equities research analysts forecast that Heron Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.